Sep 18, 2026, 18:55 UTC
Novo Nordisk confirmed that the supply of semaglutide is stable across Canada.
Source:Sep 17, 2026, 16:44 UTC
The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed Novo Nordisk's hemophilia A therapy.
Source:Sep 17, 2026, 16:44 UTC
Novo Nordisk launched a major cardiometabolic research partnership.
Source:Sep 17, 2026, 11:06 UTC
Novo Nordisk reported that its drug DeneciMig showed good tolerability in patients switching from eculizumab.
Source:Sep 17, 2026, 11:00 UTC
Orbis Medicines announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases, worth up to USD 1.4 billion.
Sep 16, 2026, 22:46 UTC
Novo Nordisk (NVO) shares closed at $41.67, down 2.02% from the previous trading session.
Source:Sep 16, 2026, 12:00 UTC
Novo Nordisk will use Claude Science to carry out its research and development workflows.
Source:Sep 16, 2026, 12:00 UTC
Novo Nordisk partnered with Anthropic to use Claude to advance drug discovery and development.
Sep 15, 2026, 14:33 UTC
Novo Nordisk CEO Mike Doustdar urged employees to adopt a more customer-focused culture as the company seeks to regain ground in the obesity drug market.
Source:Sep 14, 2026, 20:37 UTC
Eli Lilly said its oral weight-loss drug Foundayo has captured more than 30% of new US patients on oral obesity treatments, narrowing Novo Nordisk's early lead with its Wegovy pill.
Source:Sep 14, 2026, 13:14 UTC
Novo Nordisk launched a share buyback program.
Source:Sep 14, 2026, 09:45 UTC
Novo Nordisk is introducing Ozempic for diabetes care and Wegovy for weight management in Kenya.
Sep 14, 2026, 08:32 UTC
Novo Nordisk announced a brand refresh simplifying its everyday name to "Novo" while keeping the legal name Novo Nordisk A/S, aiming to regain weight-loss drug market share.
Sep 14, 2026, 05:02 UTC
Danish pharmaceutical company Novo Nordisk confirmed it will rebrand by changing its name to "Novo", dropping "Nordisk", and updating its logo and brand tagline, with the changes to be announced before its September 21 capital markets day.
Sep 11, 2026, 04:30 UTC
The High Court in Pretoria dismissed iDexis' application for leave to appeal the interim order barring it from selling compounded semaglutide products, with Judge Petrus van Niekerk calling the application an abuse of process.
Source:Sep 11, 2026, 03:55 UTC
In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.
Source:Sep 10, 2026, 22:46 UTC
Novo Nordisk (NVO) shares closed at $44.01, down 1.23% from the previous trading session.
Source:Sep 10, 2026, 06:22 UTC
Novo Nordisk's long-acting growth hormone somapacitan injection (brand name Sogroya) received approval in China for three new pediatric indications: Noonan syndrome-associated growth failure, idiopathic short stature, and short stature in children born small for gestational age, all for patients aged 2.5 years and older.
Source:Sep 10, 2026, 02:54 UTC
China's National Medical Products Administration approved the metabolic dysfunction-associated steatohepatitis (MASH) indication for semaglutide injection (brand name NovoWell) for non-cirrhotic adults with MASH and moderate-to-severe liver fibrosis (F2-F3).
Sep 7, 2026, 11:44 UTC
Novo Nordisk halted two additional trials of its experimental cardiovascular drug ziltivekimab on Monday, September 7, 2026.
Source:Sep 7, 2026, 11:13 UTC
Novo Nordisk halted two cardiovascular trials (HERMES and ATHENA) of its drug ziltivekimab after a data monitoring committee found they were unlikely to succeed, following the earlier failure of the ZEUS trial.
Source:Sep 7, 2026, 10:00 UTC
Novo Nordisk announced Phase 3 STEP YOUNG clinical data showing that 40.4% of obese children treated with semaglutide plus lifestyle intervention achieved BMI below the obesity threshold.
Sep 5, 2026, 12:00 UTC
Novo Nordisk announced that Andrea Haegebarth will join as Senior Vice President of Global Research, replacing Jacob Petersen, who will become Head of R&D External Innovation, effective 1 October 2026.
Source:Sep 4, 2026, 05:00 UTC
The foundation that controls Novo Nordisk A/S is building a $62 million quantum chip factory in Copenhagen, Denmark.
Source:Sep 2, 2026, 19:15 UTC
Aspen Pharmacare is pursuing the market for generic semaglutide, having obtained regulatory approval in Canada and awaiting registration in about 20 countries including Brazil and South Africa.
Source:Aug 31, 2026, 23:17 UTC
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.
Aug 29, 2026, 22:45 UTC
Thousands of individual lawsuits have been filed in the U.S. District Court for the Eastern District of Pennsylvania against Novo Nordisk and Eli Lilly, alleging that they failed to adequately warn patients about gastrointestinal risks (gastroparesis, ileus, intestinal blockage) associated with their diabetes and obesity drugs Ozempic, Wegovy, Mounjaro, and Zepbound.
Source:Aug 28, 2026, 04:00 UTC
Novo Nordisk and Eli Lilly are using court orders and public campaigns to combat counterfeit weight-loss drugs.
Source:Aug 25, 2026, 23:59 UTC
The U.S. federal government, through CMS, announced the BALANCE Model allowing state Medicaid programs to join between May 2026 and January 1, 2027, to negotiate discounted prices for weight-loss drugs, but as of mid-August 2026 no participating states have been named.
Source:Aug 11, 2026, 15:15 UTC
The Delhi High Court directed Sun Pharma to obtain court approval before launching semaglutide tablets, following a patent infringement suit filed by Novo Nordisk.
Source:Jul 15, 2026, 00:45 UTC
Eli Lilly launched its oral weight-loss drug Foundayo in April 2026.
Page 1Next →